BioCentury
ARTICLE | Clinical News

EMA reviewing Aeterna Zentaris' Macrilen to evaluate AGHD

December 8, 2017 4:07 AM UTC

EMA accepted for review an MAA from Aeterna Zentaris Inc. (TSX:AEZS; NASDAQ:AEZS) for Macrilen macimorelin acetate (Macrimorelin-GHST, AEZS-130) to evaluate adult growth hormone deficiency (AGHD)...

BCIQ Company Profiles

Aeterna Zentaris Inc.

BCIQ Target Profiles

Ghrelin receptor (GHSR)